In situ Pulmonary Artery Thrombosis: A Previously Overlooked Disease
Pulmonary thromboembolism (PTE) is the third leading cause of death in cardiovascular diseases. PTE is believed to be caused by thrombi detached from deep veins of lower extremities. The thrombi travel with systemic circulation to the lung and block pulmonary arteries, leading to sudden disruption o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.671589/full |
| _version_ | 1819098550304243712 |
|---|---|
| author | Yunshan Cao Chao Geng Yahong Li Yan Zhang |
| author_facet | Yunshan Cao Chao Geng Yahong Li Yan Zhang |
| author_sort | Yunshan Cao |
| collection | DOAJ |
| description | Pulmonary thromboembolism (PTE) is the third leading cause of death in cardiovascular diseases. PTE is believed to be caused by thrombi detached from deep veins of lower extremities. The thrombi travel with systemic circulation to the lung and block pulmonary arteries, leading to sudden disruption of hemodynamics and blood gas exchange. However, this concept has recently been challenged by accumulating evidence demonstrating that de novo thrombosis may be formed in pulmonary arteries without deep venous thrombosis. On the other hand, chronic thromboembolic pulmonary hypertension (CTEPH), a subtype of pulmonary hypertension, could have different pathogenesis than traditional PTE. Therefore, this article summarized and compared the risk factors, the common and specific pathogenic mechanisms underlying PTE, in situ pulmonary artery thrombosis, and CTEPH at molecular and cellular levels, and suggested the therapeutic strategies to these diseases, aiming to facilitate understanding of pathogenesis, differential diagnosis, and precision therapeutics of the three pulmonary artery thrombotic diseases. |
| first_indexed | 2024-12-22T00:32:46Z |
| format | Article |
| id | doaj.art-172ed9d4ad0848f6a7798f983697f9b3 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-22T00:32:46Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-172ed9d4ad0848f6a7798f983697f9b32022-12-21T18:44:53ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-07-011210.3389/fphar.2021.671589671589In situ Pulmonary Artery Thrombosis: A Previously Overlooked DiseaseYunshan Cao0Chao Geng1Yahong Li2Yan Zhang3Department of Cardiology, Gansu Provincial Hospital, Lanzhou, ChinaTianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, ChinaTianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, ChinaTianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, ChinaPulmonary thromboembolism (PTE) is the third leading cause of death in cardiovascular diseases. PTE is believed to be caused by thrombi detached from deep veins of lower extremities. The thrombi travel with systemic circulation to the lung and block pulmonary arteries, leading to sudden disruption of hemodynamics and blood gas exchange. However, this concept has recently been challenged by accumulating evidence demonstrating that de novo thrombosis may be formed in pulmonary arteries without deep venous thrombosis. On the other hand, chronic thromboembolic pulmonary hypertension (CTEPH), a subtype of pulmonary hypertension, could have different pathogenesis than traditional PTE. Therefore, this article summarized and compared the risk factors, the common and specific pathogenic mechanisms underlying PTE, in situ pulmonary artery thrombosis, and CTEPH at molecular and cellular levels, and suggested the therapeutic strategies to these diseases, aiming to facilitate understanding of pathogenesis, differential diagnosis, and precision therapeutics of the three pulmonary artery thrombotic diseases.https://www.frontiersin.org/articles/10.3389/fphar.2021.671589/fullpulmonary thromboembolismin situ pulmonary thrombosisdeep venous thrombosischronic thromboembolic pulmonary hypertensionrisk factorspathogenic mechanism |
| spellingShingle | Yunshan Cao Chao Geng Yahong Li Yan Zhang In situ Pulmonary Artery Thrombosis: A Previously Overlooked Disease Frontiers in Pharmacology pulmonary thromboembolism in situ pulmonary thrombosis deep venous thrombosis chronic thromboembolic pulmonary hypertension risk factors pathogenic mechanism |
| title | In situ Pulmonary Artery Thrombosis: A Previously Overlooked Disease |
| title_full | In situ Pulmonary Artery Thrombosis: A Previously Overlooked Disease |
| title_fullStr | In situ Pulmonary Artery Thrombosis: A Previously Overlooked Disease |
| title_full_unstemmed | In situ Pulmonary Artery Thrombosis: A Previously Overlooked Disease |
| title_short | In situ Pulmonary Artery Thrombosis: A Previously Overlooked Disease |
| title_sort | in situ pulmonary artery thrombosis a previously overlooked disease |
| topic | pulmonary thromboembolism in situ pulmonary thrombosis deep venous thrombosis chronic thromboembolic pulmonary hypertension risk factors pathogenic mechanism |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.671589/full |
| work_keys_str_mv | AT yunshancao insitupulmonaryarterythrombosisapreviouslyoverlookeddisease AT chaogeng insitupulmonaryarterythrombosisapreviouslyoverlookeddisease AT yahongli insitupulmonaryarterythrombosisapreviouslyoverlookeddisease AT yanzhang insitupulmonaryarterythrombosisapreviouslyoverlookeddisease |